FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/Peptide Therapy in Focus: New Study Investigates Amylin's Role in Post-Traumatic Headache
研究ライブラリに戻る

Peptide Therapy in Focus: New Study Investigates Amylin's Role in Post-Traumatic Headache

November 20, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

Peptide Therapy in Focus: New Study Investigates Amylin's Role in Post-Traumatic Headache

Peptide therapy continues to be a promising avenue for treating complex medical conditions, and recent research is shedding light on its potential impact on post-traumatic headache (PTH). A new study from the Danish Headache Center aims to explore whether pramlintide—a peptide analogue of human amylin—can induce migraine-like symptoms in individuals suffering from PTH following mild traumatic brain injury (mTBI).

Background

Headaches are a common symptom among patients who have experienced mTBI, often persisting long after the initial injury. These persistent headaches can significantly impact quality of life and pose challenges for effective treatment. Pramlintide, an FDA-approved peptide used primarily to manage diabetes by mimicking the effects of human amylin, has shown potential in other neurological conditions due to its vasoactive properties.

Amylin is a hormone that plays a role in glucose regulation but also affects blood vessels and may contribute to headache mechanisms. The Danish Headache Center's study seeks to understand if pramlintide, which closely mimics the structure and function of amylin, could exacerbate or trigger headaches in individuals with PTH. This research aims to provide valuable insights into the underlying causes of these persistent headaches and potentially identify new treatment options.

Key Details

The clinical trial (NCT07340775) is currently recruiting participants who have experienced mTBI within the past year and are suffering from ongoing post-traumatic headache. The study will compare the effects of pramlintide, a synthetic peptide that closely resembles human amylin, with a placebo to determine if there is any correlation between amylin-like peptides and the onset or worsening of migraine symptoms in these patients.

Participants will be carefully monitored for changes in their headache patterns after receiving either pramlintide or a placebo. Researchers hope to gather data on how this peptide influences blood vessel dilation and constriction, which are key factors in migraines and other types of headaches. Understanding these mechanisms could lead to more targeted therapies for individuals struggling with PTH.

Key Takeaways

  • Exploring Amylin's Role: The study aims to investigate the relationship between amylin-like peptides and post-traumatic headache symptoms.
  • Potential New Insights: By comparing pramlintide (a synthetic version of human amylin) with a placebo, researchers hope to uncover new information about the underlying causes of PTH.
  • Implications for Treatment: If pramlintide is found to influence headaches in this population, it could pave the way for innovative treatment approaches using peptide therapy.
  • Patient Participation Needed: The study requires volunteers who have experienced mTBI and ongoing headache symptoms to participate and contribute valuable data.

What This Means

For the peptide research community, this trial represents a significant step towards understanding how specific peptides might influence neurological conditions beyond their primary therapeutic applications. It highlights the potential for cross-disciplinary insights into pain management and neurology through targeted peptide interventions. As more studies like this one continue to explore the diverse roles of peptides in health and disease, we may see an expansion of treatment options that leverage these powerful biological molecules.

---

Source: ClinicalTrials.gov — Published 2026-11-20

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。